Evaluation of the effect of oral selenium administration on tremor reduction of Parkinsonians

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201101155612N1

Enrollment

Registered

2014-01-09

Start date

2014-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tremor. Parkinson disease

Interventions

First intervention: one capsule (placebo or 200 mg selenium) daily for 2 months will be prescribed to 26 patients and indices will be measured at first and the end. Second intervention: after 2 week'

Treatment - Drugs

First intervention: one capsule (placebo or 200 mg selenium) daily for 2 months will be prescribed to 26 patients and indices will be measured at first and the end. Second intervention: after 2 week

Eligibility

Sex/Gender

All

Age

40 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusions: Idiopathic Parkinson disease; Age between 40 and 60 years; 6 months after diagnosis the disease; stage 2.5 or less based on MODIFIED HOEHN AND YAHR STAGING 5 ; Apparent or troublesome tremor Exclusions:Other disease induses tremor; out of age range between 40 to 60 years

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Tremor rate. Timepoint: At beginning, End of 2 months. Method of measurement: Based on exam,Observation and Physical exam, indices (0-16) will be measured every 2 months (before and after treatment).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Mellat Ardekani

Yazd University of Medical Sciences

ali_mellat@ssu.ac.irali_mellat@yahoo.com+98 35 1822 4001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026